
A recent study analyzed patients with atopic dermatitis (AD) who developed musculoskeletal symptoms after receiving dupilumab treatment, an IL‐4 receptor antagonist. Among 470 patients, 26 developed inflammatory enthesitis, arthritis, and/or tenosynovitis. Imaging confirmed the findings, and most patients responded well to dupilumab. However, some experienced persistent moderate to severe symptoms even after dose adjustments or therapy cessation.
Like
Save
Share